Key clinical highlights and key takeaways from ECCMID 2022 are discussed in this interview with touchINFECTIOUS DISEASES Editorial Board member, Dr Evangelos Giamarellos-Bourboulis (Attikon University Hospital, Chaidari, Greece; Chair, European Sepsis Alliance). He discusses the burden of drug resistance in antimicrobials, and the main drugs in the market and emerging treatments. He also discusses his thoughts on the latest advances in his research group.
- What are the key clinical highlights from ECCMID 2022? (0:16)
- What are the hot topics and latest research you are looking forward to exploring in 2022? (3:07)
Disclosures: Evangelos Giamarellos-Bourboulis receives honoraria (paid to the University of Athens) from Abbott CH, Brahms, ThermoFisher GmbH Germany, GSK, and Sobi; he is also a consultant for Abbott CH, Fab’nTech, InflaRx GmbH, UCB, Sobi, and Xbiotech Inc; he also receives research grants (paid to the University of Athens) from AbbVie USA, InflaRx GmbH, Novartis, and UCB; he also receives research grants (paid to the Hellenic Institute for the Study of Sepsis) from Abbott CH, bioMérieux France, Johnson & Johnson, MSD, Sobi, and ThermoFisher Brahms GmbH. Evangelos Giamarellos-Bourboulis also received EU research funding from Horizon 2020 ITN European Sepsis Academy (granted to the University of Athens), Horizon 2020 ImmunoSep and RISCin COVID (granted to the Hellenic Institute for the Study of Sepsis), and Horizon 2020 EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In COVID-19
Ruth Link-Gelles, IDWeek 2022: Efficacy of COVID-19 vaccination in paediatric populations
In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss the incidence of COVID-19 in children, vaccine effectiveness against infection and disease severity, and the current status of paediatric COVID-19 vaccines in the United States. Interviews available in this series: Real world […]
Ruth Link-Gelles, IDWeek 2022: Real world effectiveness of paediatric COVID-19 vaccination
COVID-19 typically causes less severe illness and fewer deaths in children and adolescents compared to adults. Nonetheless, children and adolescents remain susceptible to COVID-19 infection and can transmit to others. In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss real-world findings of […]
Angus Thomson: Communicating with patients about their vaccinations – Communication methods, support and counteracting disinformation
In this interview, Dr Angus Thomson (Irimi Company, Lyon, France) discusses effective methods for communicating with patients about their vaccinations, how healthcare professionals (HCPs) can help to counteract disinformation, and additional resources for HCPs and patients. Interviews available in this series: Angus Thomson: Barriers to vaccine acceptance in a post-COVID world Angus Thomson: Zero-dose children: […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!